Updates are available Correction dated 2025-03-28
Click to view Correction: https://doi.org/10.1007/s10741-025-10507-0
-
Authors
Fonseca, Cândida
Baptista, Rui
Franco, Fátima
Moura, Brenda
Pimenta, Joana
Moraes Sarmento, Pedro
Cardoso, José Silva
Brito, Dulce
- License Information
-
More Information
Article History
Accepted: 11 February 2025
First Online: 20 February 2025
Change Date: 27 March 2025
Change Type: Update
Change Details: The original online version of this article was revised to present the correct first and last names of the authors.
Change Date: 28 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10741-025-10507-0
Declarations
:
: The manuscript does not contain clinical studies or patient data.
: CF received consultancy fees, grants, and speaker’s honoraria from Astra Zeneca, Bayer, Bial, Boehringer Ingelheim, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Servier, and CSLVifor. RB received speaker, advisory board, and grant funding fees from AstraZeneca, Bayer, Bial, Boehringer Ingelheim, Lilly, Menarini, Merck, MSD, Novartis, Pfizer, Servier Portugal, and Vifor Pharma. FF received consultant fees from Bayer, AstraZeneca, Boehringer Ingelheim, and Medinfar. BM received consultant or speaking fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Servier, Novartis, Vifor pharma, and Viatris. JP received speaker and consultant fees from Astra Zeneca, Bayer, Bial, Boehringer-Ingelheim, Lilly, Merck, Novartis, Pfizer, Roche diagnostics, Servier, and CSL Vifor. PMS received consultant or speaking fees from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, and Pfizer. JSC received research, consultant, or speaking fees from AstraZeneca, Bayer, Bial, Boehringer Ingelheim, Eli Lilly, Novartis, Pfizer, Servier, and Vifor Pharma. DB received consultancy fees and lectures or scientific meeting sponsorship from Alnylam, AstraZeneca, Bayer, Bial, Boehringer Ingelheim, Novartis, and Pfizer.
